Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Xencor to “hold” from “strong sell,” while the broader analyst consensus remains “hold,” with five buy ratings, three holds and one sell rating and an average price target of $24.86.
• Xencor’s latest quarterly results beat expectations: the company reported a $0.29-per-share loss versus an expected $0.80 loss, while revenue of $51.22 million exceeded the $18.89 million consensus and rose 17.4% year over year.
• Despite stronger results and several bullish analyst targets, profitability remains a key risk; Xencor continues to post substantial net losses and analysts expect a full-year loss of $3.76 per share.

Xencor (NASDAQ:XNCR - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Several other equities analysts also recently issued reports on XNCR. Cantor Fitzgerald increased their price objective on shares of Xencor from $43.00 to $44.00 and gave the company an "overweight" rating in a report on Thursday. Truist Financial reduced their target price on Xencor from $29.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, July 7th. JPMorgan Chase & Co. lifted their price target on Xencor from $13.00 to $14.00 and gave the stock a "neutral" rating in a research note on Monday, May 11th. Zacks Research raised shares of Xencor from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Finally, Royal Bank Of Canada upped their target price on shares of Xencor from $19.00 to $20.00 and gave the stock an "outperform" rating in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Xencor has an average rating of "Hold" and an average target price of $24.86.

Xencor Stock Up 4.0%

NASDAQ:XNCR opened at $20.81 on Friday. Xencor has a 52 week low of $6.92 and a 52 week high of $21.96. The stock has a market capitalization of $1.55 billion, a PE ratio of -9.59 and a beta of 0.85. The stock's 50-day moving average price is $15.69 and its 200-day moving average price is $13.37.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analysts' expectations of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.Xencor's quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.41) EPS. Sell-side analysts expect that Xencor will post -3.76 earnings per share for the current fiscal year.

Institutional Trading of Xencor

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Xencor in the first quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Xencor by 9.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company's stock worth $471,000 after acquiring an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company's stock valued at $7,732,000 after purchasing an additional 344,088 shares during the period. Creative Planning lifted its stake in shares of Xencor by 25.3% in the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company's stock valued at $143,000 after purchasing an additional 3,661 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Xencor by 170.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company's stock valued at $2,594,000 after purchasing an additional 208,182 shares during the last quarter.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source